TX-SPINALCYTE,-LLC
SpinalCyte, LLC, a clinical stage regenerative medicine company focused on regrowth of the spinal disc using Human Dermal Fibroblasts (HDFs), today announced a new comprehensive resource to raise awareness of the potential benefits of fibroblasts and provide a growing knowledge base for this promising regenerative medicine technology.
The company’s website, www.spinalcyte.com , now features company and independent research studies demonstrating the potential of this new cell source for disc repair and other disease pathways.
“Fibroblasts hold significant advantages over mesenchymal stem cells,” said Dr. Thomas Ichim, Chief Scientific Officer of SpinalCyte and author of an analysis comparing the two cell sources published in the Journal of Translational Medicine . “As we and other leading researchers continue to advance the science in this field, our website will be the best place to find the latest and most up-to-date information on the healing power of fibroblasts.”
SpinalCyte is the leader in the field of HDF therapy with 52 U.S. and international patents issued and 85+ patents pending focused on the clinical utility of fibroblasts.
“Fibroblasts are the regenerative cell source of the future,” said Pete O’Heeron, Chief Executive Officer of SpinalCyte. “The breadth of our intellectual property demonstrates the versatility of this technology and positions us as the unquestioned frontrunner in this emerging sector. We look forward to presenting new research from around the globe highlighting the promise of fibroblasts.”
About Degenerative Disc Disease
Degenerative disc disease (DDD) is a condition in which a patient’s spinal disc breaks down and can begin to collapse. It is estimated that 85% of people over the age of 50 have evidence of disc degeneration and over 1.3 million procedures a year are performed to treat the disease. The most common treatments for patients with DDD are either discectomy or spinal fusion. Discectomy is the partial or full removal of the degenerated disc to decompress and relieve the nervous system but can cause long term spinal pain. In a spinal fusion procedure, the entire disc is removed and the two adjacent vertebrae are fused together. It often increases strain on the adjacent discs and surrounding tissues leading to further degeneration.
About CybroCell
CybroCell is the first off-the-shelf allogenic human dermal fibroblast (HDF) product for the treatment of degenerative disc disease. SpinalCyte’s Phase 1/Phase 2 clinical trial for injected human dermal fibroblasts in the treatment of DDD demonstrated after 18 months, patients injected with CybroCell had sustained improvement in pain relief and increased back mobility.
About SpinalCyte
Based in Houston, Texas, SpinalCyte, LLC, is a regenerative medicine company developing an innovative solution for spinal disc replacement using human dermal fibroblasts. Currently, SpinalCyte holds 52 U.S. and international issued patents and has filed for an additional 85+ patents pending and issued across a variety of clinical pathways, including disc degeneration, cancer, diabetes, liver failure and heart failure. SpinalCyte represents the next generation of medical advancement in cell therapy. Visit www.spinalcyte.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190515005305/en/
Contact:
David Schull or Ned Berkowitz Russo Partners LLC 858-717-2310 646-942-5629 david.schull@russopartnersllc.com ned.berkowitz@russopartnersllc.com
Clinical Contact: info@spinalcyte.com
Link:
Social Media:
https://www.facebook.com/LibertyStarLBSR/#!/pages/Liberty-Star-Uranium-Metals-Corp/135810219778400?r
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Berkshire Hathaway Specialty Insurance Names David Lee Global Chief Human Resources Officer12.1.2026 16:27:00 CET | Press release
Berkshire Hathaway Specialty Insurance (BHSI) today announced the promotion of David Lee to Global Chief Human Resources Officer. “I am thrilled to have David leading our human resources group worldwide,” said Peter Eastwood, President and Chief Executive Officer, BHSI. “An experienced HR practitioner and lifelong student of the profession, his deep expertise, stellar work ethic, and commitment to BHSI values will continue to drive success across our global talent and HR initiatives.” David succeeds Kim Briones, who has led BHSI’s HR group since the company’s founding in 2013 and is retiring from her full-time role. “I want to express my sincere gratitude to Kim for her partnership and friendship over many years and for her outstanding leadership in building our HR function from the ground up,” Peter added. “She has played a pivotal role in growing and developing our company’s greatest asset – our global team of individuals with excellent capabilities and strong character – and in help
Owkin Advances Frontier Model Development for Biological Artificial Super Intelligence, Accelerated by NVIDIA12.1.2026 16:00:00 CET | Press release
Collaboration Leverages NVIDIA's Open Models, AI Infrastructure and Expertise to Build Next-Generation Biological Reasoning Models for Drug Development Owkin, an AI company on a mission to solve the complexity of biology, today announced a collaboration with NVIDIA to enhance OwkinZero, Owkin's biological large reasoning model. The collaboration will leverage NVIDIA's advanced AI computing ecosystem, including the Nemotron family of open models and the NVIDIA NeMo framework to improve the performance, scalability, guardrails, and robustness of Owkin's biological reasoning capabilities to accelerate future breakthroughs in drug discovery and development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112573701/en/ Owkin Advances Frontier Model Development for Biological Artificial Super Intelligence, Accelerated by NVIDIA. This marks Owkin's first collaboration with NVIDIA and represents a significant milestone in building
SecurityBridge Announces CEO Transition to Accelerate Global Expansion12.1.2026 15:15:00 CET | Press release
SecurityBridge, a leading provider of cybersecurity solutions for SAP, today announced the appointment of Jesper Zerlang as Chief Executive Officer, effective January 1, 2026. Zerlang transitions from his role as Chairman of the Board, a position he has held for the past 12 months, as the company enters its next phase of international expansion, backed by funds advised by BUBregal Unternehmerkapital (BU). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112824449/en/ Jesper Zerlang appointed Chief Executive Officer, SecurityBridge SecurityBridge protects SAP environments for large enterprises by reducing cyber risk across mission-critical SAP landscapes. The company is trusted by global customers to safeguard systems that power core operations, financial processes, supply chains, and digital transformation programs. “SecurityBridge is uniquely positioned at the intersection of cybersecurity and SAP – a domain I know deeply
New Clinical Study Publication Validates Respiratory Outcomes for the Onera Home-polysomnography System12.1.2026 14:30:00 CET | Press release
The results of this study provide further clinical evidence that patient-applied, patch-based PSG is a viable alternative to in-lab PSG, enabling broader access to gold-standard sleep testing. Onera Health, a leader in transforming sleep medicine, announces the recent publication of a multicenter validation study of its Onera Sleep Test System (STS) in the ERJ Open Research, a leading, fully open-access scientific journal published by the European Respiratory Society (ERS). This is the second publication from this study, and it demonstrates that the patch-based Onera STS home-polysomnography (hPSG) device accurately identifies respiratory events and distinguishes AHI severity when validated against simultaneous in-lab polysomnography and is a viable option for unattended home use. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112821647/en/ Patient sleeps with the patient-applied Onera home Polysomnography (Onera hPSG) so
Riskified Analysis Reveals 1 in 4 Refund Dollars Is Abusive; Introduces "Dynamic Returns," a New Policy Protect Feature, to Safeguard Revenue While Increasing Customer Satisfaction12.1.2026 14:00:00 CET | Press release
Riskified (NYSE: RSKD) a leader in ecommerce fraud and risk intelligence, today released a research analysis highlighting a growing customer experience dilemma: As merchants tighten controls to fight a surge in return and refund abuse, they are inadvertently creating a more restrictive and frustrating experience for their best customers. To help retailers mitigate this challenge, Riskified has introduced a new feature in its Policy Protect solution, Dynamic Returns, AI-powered return decisions that adapt in real-time based on customer eligibility. Riskified's 2024 analysis of over a million refund claims found that 1-2% of total order value measured in sales dollars was requested back as refunds, with nearly 1 in 4 dollars claimed being abusive. In response to rising abuse, many retailers are implementing restrictive tactics like flat return fees, shorter return windows, and delaying refunds, often taking 10+ days for warehouse inspection. These measures frustrate good customers, as 68
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom